New synaptic and molecular targets for neuroprotection in Parkinson's disease (original) (raw)

A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease

Joanne Nash

The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000

View PDFchevron_right

New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders

Karen Østergaard

Biogerontology, 2001

View PDFchevron_right

Cellular and Synaptic Dysfunctions in Parkinson’s Disease: Stepping out of the Striatum

Jérôme Baufreton

Cells

View PDFchevron_right

Neurodegenerative signaling factors and mechanisms in Parkinson's pathology

Neeraj Joshi

Toxicology in Vitro, 2017

View PDFchevron_right

Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine

J. Grizzell

Frontiers in Aging Neuroscience

View PDFchevron_right

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials

Erwan Bezard

Trends in Pharmacological Sciences, 2004

View PDFchevron_right

Neurodegenerative Pathways in Parkinsons Disease: Therapeutic Strategies

Paula Moreira

Current Drug Target -CNS & Neurological Disorders, 2005

View PDFchevron_right

NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease

Sophie Roy

European Journal of Neuroscience, 2001

View PDFchevron_right

Current and Potential Treatments of Parkinson's Disease

PREKSHA PATEL

View PDFchevron_right

Novel pharmacological targets for the treatment of Parkinson's disease

Graham Collingridge

Nature Reviews Drug Discovery, 2006

View PDFchevron_right

The cell biology of Parkinson’s disease

Ted Dawson

Journal of Cell Biology, 2021

View PDFchevron_right

Four main therapeutic keys for Parkinson’s disease: A mini review

Rasajna Nadella

2019

View PDFchevron_right

Inactivation of neuronal forebrain A 2A receptors protects dopaminergic neurons in a mouse model of Parkinson’s disease

Jadwiga Wardas

Journal of Neurochemistry, 2009

View PDFchevron_right

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease

Bastian Hengerer

Naunyn-Schmiedeberg's Archives of Pharmacology, 2000

View PDFchevron_right

Lesion of the subthalamic nucleus reverses motor deficits but not death of nigrostriatal dopaminergic neurons in a rat 6-hydroxydopamine-lesion model of Parkinson's disease

Vanessa Rizelio

Brazilian Journal of Medical and Biological Research, 2010

View PDFchevron_right

Neuroprotection in Parkinson's Disease: a Realistic Goal?

Giuseppe Di Giovanni

CNS neuroscience & therapeutics, 2010

View PDFchevron_right

Understanding Dopaminergic Cell Death Pathways in Parkinson Disease

patrick pierre michel

Neuron, 2016

View PDFchevron_right

Dopamine agonists in Parkinson's disease

Ron Tintner

Expert opinion on investigational …, 2003

View PDFchevron_right

Targeting adenosine A 2A receptors in Parkinson's disease

Kjell Fuxe

Trends in Neurosciences, 2006

View PDFchevron_right

Neuroprotection in Parkinson’s disease: facts and hopes

László Vecsei

Journal of Neural Transmission, 2019

View PDFchevron_right

Advances in Drug Development for Parkinson's Disease: Present Status

Harikrishna reddy

View PDFchevron_right

Neuroprotection in Parkinson’s disease; a commentary

Maria C Carreras, Federico E Micheli

Neurotoxicity Research, 2002

View PDFchevron_right

Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of Parkinson's disease

Paola Bossu

bioRxiv (Cold Spring Harbor Laboratory), 2022

View PDFchevron_right

Parkinson’s disease: will therapy move beyond dopaminergic medication?

László Vecsei

Clinical Investigation, 2011

View PDFchevron_right

Blockade of adenosine A2A receptors downregulates DARPP-32 but increases ERK1/2 activity in striatum of dopamine deficient weaver mouse

Paraskevi Poulou

Neurochemistry International, 2010

View PDFchevron_right

Targeting the Progression of Parkinson's Disease

David Moses

Current Neuropharmacology, 2009

View PDFchevron_right

Milestones in Parkinson's disease therapeutics

Olivier Rascol

Movement Disorders, 2011

View PDFchevron_right

Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease

Giulia Ferrari-toninelli

Current Topics in Medicinal Chemistry, 2008

View PDFchevron_right

Neuroprotective and neurorestorative strategies for Parkinson's disease

Ted Dawson

Nature Neuroscience, 2002

View PDFchevron_right

Pathogenesis and Treatment of Parkinson's Disease

Ganis Lintang

Academia Letters, 2021

View PDFchevron_right

Parkinson's disease and D1 dopamine receptors

Richard Mailman

Current opinion in investigational drugs (London, England : 2000), 2001

View PDFchevron_right

Molecular Targets for Improvement of Parkinson's Disease Therapy

tiziana cocco

Brain Disorders & Therapy, 2015

View PDFchevron_right

Parkinson's disease: Mechanisms, translational models and management strategies

Chand Raza

Life Sciences, 2019

View PDFchevron_right